Furthermore, mutational analysis of driver genes, such as KRAS, GNAS, or KLF4, as well as miRNA sequencing and cyst fluid telomere fusion status seem to allow the discrimination of high-risk IPMN from low risk lesions [43–47]. This evidence concerns the gene KRAS and pancreatic intraductal papillary-mucinous neoplasm.